Politiparty
Politiparty
LeaderboardCongressBills

119th Congress Health

S. 4472: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Passed SenateAug 4, 2026

  1. Introduced (completed)Apr 30, 2026
  2. Passed Senate (completed)Aug 4, 2026
  3. Passed House (not reached)
  4. To the President (not reached)
  5. Became law (not reached)

Summary

Reported to Senate, Jul 16, 2026

This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.

The bill reauthorizes

  • grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
  • grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
  • a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.
Read the full summary

Also, the bill revises the NIH grants to require (1) the NIH, in considering grant renewal, to assess available information on the safety and efficacy of the investigational drugs; (2) grantees to promptly report available safety data from ongoing clinical trials; and (3) the NIH to determine the timeframe for enrollment in clinical trials for the investigational drugs.

Additionally, every five years, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, for ALS and other rare neurodegenerative diseases. Each plan must include the FDA's previous actions and recommendations for improvements.

Finally, the Government Accountability Office and the Department of Health and Human Services must report on the impacts of these grants.

Written by the Congressional Research Service, Library of Congress.

Roll calls

0 votes on this bill

No roll call votes have been held on this bill.

Amendments

0 offered

No amendments were offered to this bill.

Cosponsors

15

Bipartisan support.

Who scored on this bill

116 points earned
  1. 1Lisa Murkowski R-AK SponsorDrew cross-party cosponsors, introduced, reported, passed Senate4 events+56
  2. 2Jim Banks R-INCosponsored; cosponsored bill passed2 events+4
  3. 2John Barrasso R-WYCosponsored; cosponsored bill passed2 events+4
  4. 2Shelley Capito R-WVCosponsored; cosponsored bill passed2 events+4
  5. 2Susan Collins R-MECosponsored; cosponsored bill passed2 events+4
See all scorers and every scoring event

Introductions and cosponsorships count toward weekly caps and show no points.

Other bills by Lisa Murkowski

History

  1. Aug 4, 2026Passed the Senate with an amendment by voice vote.
  2. Apr 30, 2026Introduced in the Senate by Lisa Murkowski.
Show the full action history (11 actions)
  1. Aug 10, 2026Received in the House.
  2. Aug 10, 2026Held at the desk.
  3. Aug 10, 2026Message on Senate action sent to the House.
  4. Aug 4, 2026Passed Senate with an amendment by Voice Vote. (consideration: CR S4425-4426; text: CR S4425-4426)
  5. Aug 4, 2026Passed/agreed to in Senate: Passed Senate with an amendment by Voice Vote.
  6. Aug 4, 2026Passed Senate with an amendment by Voice Vote.
  7. Jul 16, 2026Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
  8. Jul 16, 2026Placed on Senate Legislative Calendar under General Orders. Calendar No. 461.
  9. Jun 17, 2026Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
  10. Apr 30, 2026Introduced in Senate
  11. Apr 30, 2026Read twice and referred to the Committee on Health, Education, Labor, and Pensions.